Real-world comparative effectiveness of stroke prevention in patients with atrial fibrillation treated with rivaroxaban vs. vitamin k antagonists (RELOAD)

Study identification

• EU PAS number:
  EUPAS15755
• Study ID:
  28914
• Official title and acronym:
  Real-world comparative effectiveness of stroke prevention in patients with atrial fibrillation treated with rivaroxaban vs. vitamin k antagonists (RELOAD)
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  The aim of this study is to assess the real world comparative effectiveness of Rivaroxaban prescribed in non-valvular atrial fibrillation (NVAF) routine care patients in Germany.
• Study status:
  Finalised

Research institutions and networks

Institutions

Germany

Study timelines

Date when funding contract was signed

Planned:28/04/2016

Actual:28/04/2016

Study start date

Planned:15/10/2016

Actual:15/10/2016

Date of final study report

Planned:28/02/2017

Actual:06/10/2017

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bayer AG

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable